The upcoming earnings report will provide insights into Vivos Therapeutics' financial performance. While the estimated EPS is negative, the company beat the estimate last quarter, which could indicate potential for a similar outcome this time. However, the stock's overall negative performance over the last 52 weeks may continue to weigh on investor sentiment, making it difficult to predict short-term price movements.